Men with prostate cancer often receive a type of treatment called androgen deprivation therapy. This treatment lowers the amount of a specific hormone in the body to slow down the growth of cancer cells. While this treatment is effective against the cancer, it can sometimes weaken the bones over time, making them more likely to break.
Some patients receive a more advanced treatment plan called maximal androgen blockade. This involves combining the standard hormone therapy with a second type of medicine called an androgen receptor pathway inhibitor. This combination is often used to target the cancer more aggressively. However, a large review of many studies shows that patients receiving this combined treatment have a much higher risk of bone fractures compared to those on the standard treatment alone.
Interestingly, the study looked at different types of the second medication and found that the specific brand or type did not change the risk level. Regardless of which specific medicine was added to the standard plan, the risk of bone fractures remained high. This means that the combination therapy itself is what impacts bone health, not the specific brand of the drug used.
Because of these findings, doctors suggest that patients on these advanced treatment plans should be monitored closely for bone health. A common way to manage this is by using a bone-protecting agent. These medications help strengthen the bones and reduce the chance of fractures. Doctors generally recommend these protective medicines for patients who are expected to stay on the combined treatment for a long period.
In summary, while the combination of medications is a powerful way to fight prostate cancer, it does come with a higher risk of bone damage. By identifying this risk early, doctors can work with patients to include protective treatments. This helps ensure that patients can receive strong cancer treatment while keeping their bones strong and healthy.
